MedTrace Logo

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

NCT00576251 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 221

Last updated 2010-03-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis

Conditions

  • Ocular Inflammation Associated With Blepharaconjunctivitis

Interventions

DRUG

Tobramycin 0.3%/Dexamethasone 0.05%

Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days

DRUG

TOBRADEX

TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Michael Brubaker, BSN MPH · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-02-29
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00576251 on ClinicalTrials.gov